 (Gut 1995; 36: 771-777) 
glucose (FDG) in the detection of pancreatic cancer and its differentiation from chronic pancreatitis. Eighty patients admitted for elective pancreatic surgery received preoperatively 250-350 mBq FDG intravenously and emission scans were recorded 45 minutes later. Intense focal activity in the pancreatic region was taken at the time of scanning as showing the presence of pancreatic cancer. The presence of cancer was later confirmed by histological examination of the surgical specimens and histological findings were compared with the preoperative PET results. Forty one patients with pancreatic cancer (group I: n=42) had a focally increased FDG uptake in the pancreatic region. Two patients with a periampullary carcinoma (group II: n=6) failed to develop FDG accumulation. In 28 patients with chronic pancreatitis ( Among gastrointestinal cancers, pancreatic carcinoma has the worst prognosis: less than 20% of affected patients survive the first year after diagnosis. This poor outcome may result from the frequent late diagnosis of the disease when it has reached stages III or IV, and the tumour has spread to lymph nodes or distant metastases, or both are already present. [1] [2] [3] Diagnosis of pancreatic cancer may be difficult, as clinical symptoms are rather unspecific and non-invasive imaging methods such as ultrasonography or contrast enhanced computed axial tomography (CAT) only detect indirect signs of the tumour such as a pancreatic mass or ductal abnormalities.
Positron emission tomography (PET) has recently been developed as a non-invasive imaging method for tissue characterisation based more on specific tissue metabolism rather than on imaging tissue mass, contour, echogeniety or x ray absorption. Thus, increased glucose utilisation, a metabolic hallmark of many malignant tumours,4 has been used for non-invasive identification of malignant primary or recurrent colorectal cancer, as well as cancer in the lung, head, neck, and brain. [5] [6] [7] [8] [9] [10] In these studies the glucose analogue 2 [18F]-fluoro-2-deoxy-Dglucose (FDG) has been used to measure overall tumour glucose utilisation with PET.1'
In pancreatic disorders, PET with "C-labelled L-methionine cannot distinguish pancreatic cancer from chronic pancreatitis. '2 In contrast, previous studies show that FDG-PET seems to have a higher accuracy in the diagnosis of pancreatic cancer and to be effective in the differentiation of cancer from chronic inflammation. ' 'o+(077%), the localisation. By scanning 31.5 cm downwards 00 Ci/mmol at from the liver dome the pancreatic bed was were injected always located in the scanning area.
ours of FDG
After transmission scanning with a Ge-68/Ga-68 ring source, 250-350 mBq FDG was injected into an antecubital vein and flushed with 10 ml saline. The patient was injected intravenously with furosemide (20 ECAT 931-08 mg) and was instructed to urinate as often as le, TN, USA), possible to avoid unnecessary exposure of the is slices (slice bladder and to reduce measurement artifacts primary and caused by high radioactivity in the urinary )n.
system. In preliminary studies without diuretic east six hours treatment, FDG contaminated urine in the scans were urinary system was found in most cases to )ns covering a reduce image quality and analysis (data not position of the shown). The (Table III) .
Imaging
High quality FDG-PET images of the upper abdomen were obtained using the iterative reconstruction approach for imaging generation.20 As known from previous PET studies in patients with various non-pancreatic cancers, glucose utilisation in the normal pancreas is very low in the fasting state and comparable with soft tissue background. As  Fig 2 shows, the normal pancreas is not visualised by FDG-PET. There is moderate glucose uptake in the liver and some FDG uptake in the renal parenchyma and in the urinary collecting system. Using furosemide, FDG retention in the urinary system could be considerably reduced, thus improving image quality considerably (data not shown). Figure 3 shows a typical FDG-PET image in a patient with pancreatic adenocarcinoma and stage III disease. The pancreatic mass noted in CAT had greatly increased FDG uptake. Similarly 41 of 42 patients with pancreatic cancer (group I) had a focally increased FDG uptake, amounting to a PET sensitivity of 98% for pancreatic cancer detection. The median standard uptake value was 3.09 (interquartile range: 2.18) in this group of patients (Fig 4,  Table IV ). The median standard uptake value was significantly higher than in group III (3'09 versus 0.87, p<0 001) (Fig 4, Table IV) . Four of six patients with periampullary cancer were positive as judged by FDG-PET. Taking the cancer patients together the sensitivity was 94% (45 of 48). All patients with stage III and IV (pancreatic cancer and periampullary cancer) showed focally increased FDG accumulation in PET, compared with five of eight patients (63%) with stages I and II disease.
Qualitative evaluation
In 28 of 32 patients suffering from chronic pancreatitis, the pancreas was not visualised by FDG-PET, giving a specificity of 88% for a malignant lesion. The median standard uptake the basic standard uptake value and the tumour/background ratios in patients of group I (pancreatic cancer) and group II (periampullary carcinoma) versus group III (chronic pancreatitis) was statistically significant (p<0001).
Diagnostic accuracy of CAT Analysis of CAT for diagnosis of pancreatic cancer, performed in all patients preoperatively, yielded a sensitivity and specificity of 79% (33 of 42) and 69% (22 of 32), respectively.
Tumour stages I and II were present in two patients with periampullary carcinoma and six patients with pancreatic cancer. A suspicious tumour mass was detectable by CAT in three of these patients (38%). x2 analysis showed that PET had a significant higher sensitivity for pancreatic cancer detection than CAT (p<O0O1).
The positive and negative predictive values of CAT were 77% and 7 10%, respectively.
Discussion
This study shows that FDG-PET represents a new procedure for the diagnosis of cancer of the pancreas and the periampullary region with a sensitivity higher than 90°/0. FDG-PET also proved most successful in the differentiation of pancreatic cancer from chronic pancreatitis, in particular if in the second group the pancreatic head region is enlarged. The specificity of FDG-PET within this group of patients was 88%.
Cancer of the pancreas still has a very poor prognosis, unless it is diagnosed at an early and resectable stage. -3 22 Our data show a relation between FDG accumulation and the size of the tumour. While all patients in advanced tumour stages (III-IV) had a focally increased accumulation in PET images, only five of eight patients in early stages showed increased FDG uptake.
Plasma glucose concentrations did not influence FDG uptake in the fasting state: standard uptake value and tumour/background ratio did not correlate with plasma glucose concentrations. Although there is evidence to suggest that diabetes mellitus may be responsible for false negative results,14 none of the three FDG-PET negative patients with a malignant tumour in the pancreatic region suffered from diabetes mellitus. Moreover, the size of the tumour seems to limit the diagnostic accuracy in our series of patients, as all had a tumour of stages I or II. The value of this diagnostic procedure, however, in the detection of small
Larger study populations will be required for a definite evaluation of FDG-PET in this respect.
The standard diagnostic procedures to diagnose pancreatic cancer are ultrasonography, CAT, and ERCP.23-26 Ultrasonography represents the most widely used imaging procedure in patients presenting with a suspicious pancreatic mass.23 However, the high percentage of inadequate results, the dependence upon experience of the investigator for satisfactory imaging, and its low sensitivity often require additional diagnostic procedures to be carried out. The ideal standard in the diagnosis of pancreatic cancer remains ERCP, which has accuracy rates of around 80-90%. 25 26 Only lesions that change the duct system, however, can be detected and often additional imaging procedures such as CAT are required to determine the size and the extent of the pancreatic lesion. The sensitivity of CAT to diagnose pancreatic cancer is between 50% and 90% and is based on an increase in pancreatic size, contour changes, obliteration of peripancreatic tissue or other signs of invasive or metastatic disease.24 In addition, differential diagnosis between chronic pancreatitis and pancreatic cancer by CAT is extremely difficult.
In this study, the diagnosis of pancreatic cancer was based on functional changes in the pancreatic mass caused by tumour metabolism. This represents a new approach to the diagnosis of pancreatic malignancies. FDG-PET provides comparable diagnostic accuracy, but is less invasive than ERCP. In this series of patients its diagnostic accuracy in patients with histologically confirmed pancreatic carcinomas is definitely superior to CAT. Although it was not the aim of this study to evaluate FDG-PET as a diagnostic procedure for correct staging of pancreatic cancer, liver metastasis could be identified in seven of 17 patients with a stage IV tumour. Lymph node involvement was detected in three patients. As no histological verification of this metastasis was obtained, however, definite conclusions on the value of FDG-PET for staging pancreatic cancer cannot be drawn.
In the few patients investigated thus far, PET technology using FDG provided a sensitivity of >90% in patients suffering from breast, colonic, liver, or brain cancer, and lymphoma.5-10 In our study, seven patients with pancreatic cancer that were negative by CAT showed FDG accumulation in the pancreatic tumour. In addition, three patients with pancreatic cancer in stage II could be detected by PET but not by CAT. Therefore, it seems probable that this technique might in the future contribute to the diagnosis of pancreatic cancer patients. The role of this technique, however, will be clearly defined in future larger oncological populations. emission tomography. 
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